Connect with us

Published

on

Abbott Chairman of the Board and CEO Robert B. Ford delivers a keynote address at CES 2022 at The Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada.

Ethan Miller | Getty Images

Abbott Laboratories announced on Monday it received approval from the U.S. Food and Drug Administration for two new continuous glucose monitoring systems, including one for people who don’t have diabetes. Both will be available over-the-counter without a prescription.

A continuous glucose monitor, or a CGM, is a small sensor that pokes through the skin and tracks a person’s glucose levels in real time. It wirelessly transmits this data to a smartphone. CGMs are primarily used by patients with diabetes since the tech can help alert users, their families, and their doctors to emergencies.

The market opportunity could be significant for Abbott, whose existing CGMs are already used by around 6 million patients across 60 countries, Abbot said. Around 38.4 million people are living with diabetes in the U.S. alone, Abbott said, and offering a consumer-facing CGM brings the technology to an entirely new population.

One of Abbott’s new systems, Libre Rio, is for patients with Type 2 diabetes who do not take insulin. Its second system, Lingo, is for consumers trying to improve their health and wellness, according to the company.

Abbott said Lingo users will wear a biosensor on their upper arm for 14 days at a time, and they can track their glucose data within a coaching app on their phone. Participants get access to customized coaching based on their data that can help them “retrain their metabolism and improve their overall wellbeing,” the company said.

Several companies like Signos use CGMs to help people lose weight and improve their metabolic health. Oftentimes, users need a valid CGM prescription to participate in these programs, so Abbott’s new over-the-counter offering could be more accessible for some consumers.

Libre Rio is Abbott’s first over-the-counter offering for people with diabetes in the U.S., though other CGMs within its portfolio have been available without a prescription in other countries over the last decade. Libre Rio is designed for Type 2 patients who usually manage their diabetes with lifestyle modifications, the company said.

Abbott competitor Dexcom, which also sells CGM systems, received FDA approval for its first-ever over-the-counter CGM in March.

Continue Reading

Technology

SoftBank Group shares plunge over 9% as Asian tech stocks decline

Published

on

By

SoftBank Group shares plunge over 9% as Asian tech stocks decline

The logo of Japanese company SoftBank Group is seen outside the company’s headquarters in Tokyo on January 22, 2025. 

Kazuhiro Nogi | Afp | Getty Images

Shares of SoftBank Group plunged as much as 9.17% Wednesday, as technology stocks in Asia declined, tracking losses in U.S. peers overnight.

The Japanese tech-focused investment firm saw shares drop for a second consecutive session, following its announcement of a $2 billion investment in Intel. Intel shares rose 6.97% to close at $25.31 Tuesday stateside.

Stock Chart IconStock chart icon

hide content

SoftBank Group shares

Other Japanese tech stocks also declined, with semiconductor giant Advantest falling as much as 6.27%. Meanwhile, shares in Renesas Electronics and Tokyo Electron were last seen trading 2.46% and 0.75% lower, respectively.

Technology companies in South Korea, Taiwan and Hong Kong, also fell after U.S. tech stocks dropped overnight spurred by declines in artificial intelligence darling Nvidia‘s shares.

U.S. Commerce Secretary Howard Lutnick is considering the federal government taking equity stakes in semiconductor companies that get funding under the CHIPS Act for building plants in the U.S, sources familiar with the matter told Reuters. The U.S. CHIPS and Science Act seeks to boost the country’s semiconductor industry, scientific research and innovation.

Shares of Taiwanese chip company TSMC and manufacturer Hon Hai Precision Industry — known globally as Foxconn — declined 1.69% and 2.16%, respectively. TSMC manufactures Nvidia’s high-performance graphics processing units that help power large language models, while Foxconn has a strategic partnership with Nvidia to build “AI factories.” 

Meanwhile, South Korean tech stocks mostly fell with shares of chipmaker SK Hynix down 3.33%. Samsung Electronics, however, rose 0.75%.

TSMC, Samsung and SK Hynix are among companies that have received funding under the CHIPS Act.

Over in Hong Kong, the Hang Seng Tech index lost 0.87% in early trade.

The worst performing stocks on the index were Kuaishou Technology which declined 4.8%, JD Health International which dropped 3.31% and Horizon Robotics which lost 2.29%.

Losses were also seen tech majors Alibaba Group, down 1.44%, and Xiaomi Corp which lost 1.34%.

Continue Reading

Technology

Palantir stock slumps 9%, falling for a fifth straight day from record

Published

on

By

Palantir stock slumps 9%, falling for a fifth straight day from record

CEO of Palantir Technologies Alex Karp attends the Pennsylvania Energy and Innovation Summit on the campus of Carnegie Mellon University in Pittsburgh, Pennsylvania on July 15, 2025.

Andrew Caballero-reynolds | Afp | Getty Images

Palantir‘s stock slumped more than 9% on Tuesday, falling for a fifth straight day to continue its pullback from all-time highs.

The artificial intelligence software provider’s stock has slid more than 15% over the last five trading sessions, after a stellar earnings report earlier this month propelled shares to all-time highs. The report was Palantir’s first-ever $1 billion revenue quarter.

Tuesday’s dip coincided with a broader market pullback.

Palantir is the most significant gainer to date in the S&P 500 in 2025, up more than 100%.

Read more CNBC tech news

Shares have more than doubled as the company benefits from ongoing AI enthusiasm, scooping up government contracts with President Donald Trump pushing to overhaul agencies.

Palantir’s ascent has pushed the company into a list of top 10 U.S. tech firms and 20 most valuable U.S. companies, while also making shares incredibly expensive to own. Its forward price-to-earnings ratio, which tracks future earnings relative to share price, has soared past 245 times.

By comparison, technology giants such as Microsoft and Apple carry a P/E of nearly 30 times and rake in significantly greater quarterly revenues. Meta‘s and Alphabet‘s P/E ratios hover in the 20s.

What to know about Palantir's engineer-led sales strategy

Continue Reading

Technology

Databricks says it’s valued at over $100 billion in latest funding round

Published

on

By

Databricks says it's valued at over 0 billion in latest funding round

Ali Ghodsi, CEO of Databricks speaks on CNBC.

CNBC

Databricks has just entered an exclusive club.

The data analytics software vendor said Tuesday that it’s raising a funding round that values the company at over $100 billion. That would make Databricks just the fourth private company to eclipse the $100 billion mark, following SpaceX, ByteDance and OpenAI, according to data from CB Insights.

Databricks CEO Ali Ghodsi told CNBC’s Brian Sullivan that the total round will exceed $1 billion. The company was last valued by private investors at $62 billion in a $10 billion financing round late last year.

In June, Databricks executives told investors the company was forecasting $3.7 billion in annualized revenue by July, with 50% year-over-year growth.

Snowflake, one of Databricks’ top rivals, is expected to generate $4.5 billion in revenue for the fiscal year that ends in January, representing annual growth of 25%, according to LSEG. Snowflake currently has a market cap of about $65 billion. Other competitors include cloud providers such as Amazon and Microsoft, which are also Databricks partners.

Ghodsi said he heard from a lot of interested investors following Figma’s IPO late last month. Shares of the design software company more than tripled in their New York Stock Exchange debut, a sign that public investors are seeking out tech offerings after in extended lull in the IPO market.

“My phone was blowing up,” Ghodsi said on Tuesday. “So yes, there’s definitely been a big push from outside.”

Figma shares have since retreated from their initial $115.50 closing price. The stock is trading at about $70, still more than double the $33 IPO price.

Ghodsi said the round will help Databricks invest in products that clients can tap when using artificial intelligence models.

Founded in 2013 and based in San Francisco, Databricks ranked third on CNBC’s 2025 Disruptor 50 list. As of June, the company employed 8,000 people. Existing investors Andreessen Horowitz, Insight Partners Thrive Capital and WCM Investment Management are buying shares, a spokesperson said.

WATCH: Databricks CEO on AI: VCs are wondering if agentic AI will actually automate work

Databricks CEO on AI: VCs are wondering if agentic AI will actually automate work

Continue Reading

Trending